Ignite Creation Date:
2024-05-06 @ 9:07 AM
Last Modification Date:
2024-10-26 @ 12:10 PM
Study NCT ID:
NCT02906202
Status:
COMPLETED
Last Update Posted:
2023-06-18
First Post:
2016-08-19
Brief Title:
A Study Evaluating the Efficacy and Safety of the LentiGlobin BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia Who do Not Have a β0β0 Genotype
Sponsor:
Organization:
bluebird bio
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
24
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: